Immunotherapy of Experimental Metastases by Vaccination with Interleukin Gene-Transduced Adenocarcinoma Cells Sharing Tumor-Associated Antigens: Comparison between IL-12 and IL-2 Gene-Transduced Tumor Cell Vaccines

Journal of Immunology

Volumn 157, Issue 12, 1996, Pages 5536-5542

  Rodolfo, Monica ^a   Zilocchi, Chiara ^a   Melani, Cecilia ^a   Cappetti, Barbara ^a   Arioli, Ivano ^a   Parmiani, Giorgio ^a   Colombo, Mario P ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; INTERLEUKIN 12; INTERLEUKIN 2; TUMOR ANTIGEN;

ADENOCARCINOMA; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; COLON TUMOR; CYTOTOXICITY; EXPERIMENTAL NEOPLASM; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; LYMPHOCYTE ACTIVATION; METASTASIS; MOUSE;

ADENOCARCINOMA; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; IMMUNOTHERAPY; INTERLEUKIN-12; INTERLEUKIN-2; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL;

EID: 0030589377     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol 13:251.
2. Biron, C. A., and R. Gazzinelli. 1995. Effects of IL-12 on immune responses to microbial infections: a key mediator in regulating disease outcome. Curr. Opin. Immunol. 7:485.
3. Brunda, M. J., L. Luistro, R. R. Warrier, R. B. Wright, B. R. Hubbard, M. Murphy, S. F. Wolf, and M. K. Gately. 1993. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178:1223.
4. Zou, J., N. Yamamoto, T. Fuji, H. Takenaka, M. Kobayashi, S. H. Hermann, S. F. Wolf, H. Fujiwara, and T. Hamaoka. 1995. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFNγ production by anti-tumor T cells. Int. Immunol. 7:1135.
5. Coughlin, C. M., M. Wysocka, H. L. Kurzawa, W. M. F. Lee, G. Trinchieri, and S. L. Eck. 1995. B7-1 and Interleukin-12 synergistically induce effective antitumor immunity. Cancer Res. 55:4980.
6. Brunda, M. J., L. Luistro, J. A. Hendrzak, M. Fountoulakis, G. Garotta, and M. K. Gately. 1995. Role of interferon-γ in mediating the antitumor efficacy of interleukin-12. J. Immunother. 17:71.
7. Nastala, C. L., H. D. Edington, T. G. McKinney, H. Tahara, M. A. Nalesnik, M. J. Brunda, M. K. Gately, S. F. Wolf, R. D. Schreiber, W. J. Storkus, and M. T. Lotze. 1994. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153:1697.
8. Voest, E. E., B. M. Kenyon, M. S. O'Reilly, G. Truitt, R. J. D'Amato, and J. Folkman. 1995. Inhibition of angiogenesis in vivo by interleukin-12. J. Natl. Cancer Inst. 87:581.
9. Noguchi, Y., E. C. Richards, Y. Chen, and L. J. Old. 1995. Influence of interleukin-12 on p53 peptide vaccination against established MethA sarcoma. Proc. Natl. Acad. Sci. USA 92:2219.
10. Irvine, K. R., J. B. Rao, S. A. Rosenberg, and N. P. Restifo. 1996. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J. Immunil. 156:238.
11. Vagliani, M., M. Rodolfo, F. Cavallo, M. Parenza, C. Melani, G. Parmiani, G. Forni, and M. P. Colombo. 1996. IL-12 potentiates the curative effect of a vaccine based on IL-2 transduced tumor cells. Cancer Res. 56:467.
12. Parmiani, G., and M. P. Colombo. 1995. Somatic gene therapy of human melanoma: preclinical studies and early clinical trials. Melanoma Res. 5:295.
13. Corbett, T. H., D. P. Griswold, B. J. Roberts, J. C. Peckham, and F. M. Schabel. 1975. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res. 35:2434.
14. Sato, N., M. C. Michaelides, and M. K. Wallack. 1983. Transplantation immunity and cross-protection of two cultured murine colon lines. J. Natl. Cancer Inst. 70:261.
15. Rodolfo, M., C. Bassi, C. Salvi, and G. Parmiani. 1991. Therapeutic use of a long-term cytotoxic T cell line recognizing a common tumour-associated antigen: the pattern of in vitro reactivity predicts the in vivo effect on different tumours. Cancer Immunol. Immunother. 34:53.
16. Rodolfo, M., C. Castelli, C. Bassi, P. Accornero, M. Sensi, and G. Parmiani. 1994. Cytotoxic T lymphocytes recognize tumor antigens of a murine colonic carcinoma by using different T-cell receptors. Int. J. Cancer 57:440.
17. Sato, N., T. Sato, S. Takahahi, M. Okubo, A. Yagihashi, H. Koshiba, and K. Kikuki. 1987. Identification of transformation-related antigen by monoclonal antibody on Swiss 3T3 cells induced by transfection with murine cultured colon 36 tumor DNA. J. Natl. Cancer Inst. 78:307.
18. Martinotti, A., A. Stoppacciaro, M. Vagliani, C. Melani, F. Spreafico, M. Wysocka, G. Parmiani, G. Trinchieri, and M. P. Colombo. 1995. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur. J. Immunol. 25:137.
19. + lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to produce IL-4. J. Immunol. 153:5659.
20. Pardoll, D. M. 1995. Paracrine cytokine adjuvants in cancer immunotherapy. Ann. Rev. Immunol. 13:399.
21. Maass, G., W. Schmidt, M. Berger, F. Schilcher, F. Koszik, A. Schneeberger, G. Stingl, M. L. Birnstiel, and T. Schweighoffer. 1995. Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc. Natl. Acad Sci. USA 92:5540.
22. Hock, H., M. Dorsch, U. Kunzendorf, Z. Quin, T. Diamantstein, and T. Blankenstein. 1993. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin-2, interleukin-4, interleukin-7, tumor necrosis factor α, or interferon γ. Proc. Natl. Acad. Sci. USA 90:2774.
23. Cavallo, F., F. Di Pierro, M. Giovarelli, A. Gulino, A. Vacca, A. Stoppacciaro, M. Forni, A. Modesti, and G. Forni. 1993. Protective and curative potential of vaccination with Interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res. 53:5067.
24. Allione, A., M. Consalvo, P. Nanni, P. L. Lollini, F. Cavallo, M. Giovarelli, M. Forni, A. Gulino, M. P. Colombo, P. Dellabona, H. Hock, T. Blankenstein, F. M. Rosenthal, B. Gansbacher, M. C. Bosco, T. Musso, L. Gusella, and G. Forni. 1994. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-10, TNFα, GM-CSF, and γ-IFN gene or admixed with conventional adjuvants. Cancer Res. 54:6022.
25. Colombo, M. P., and M. Rodolfo. 1995. Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: do animal studies really support clinical trials? Cancer Immunol. Immunother. 41:265.
26. Saito, S., R. Bannerji, B. Gansbacher, F. M. Rosenthal, P. Romanenko, W. D. W. Heston, W. R. Fair, and E. Gilboa. 1994. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res. 54:3516.
27. + tumor-infiltrating lymphocytes. J. Exp. Med. 173:647.
28. Lynch, D. H., A. E. Namen, and R. E. Miller. 1991. In vivo evaluation of the effects of interleukins 2, 4 and 7 on enhancing the immunotherapeutic efficacy of anti-tumor cytotoxic T lymphocytes. Eur. J. Immunol. 21:2977.
29. Porgador, A., M. Feldman, and L. Eisenbach. 1994. Immunotherapy of tumor metastasis via gene therapy. Nat. Immun. 13:113.
30. Katsanis, E., P. J. Orchard, M. A. Bausero, K. B. Gorden, R. S. McIvor, and B. Blazar. 1994. Interleukin-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of preestablished retroperitoneal tumors. J. Immunother. 15:81.
31. Viewveg, J., F. M. Rosental, R. Bannerji, W. D. W. Heston, W. R. Fair, B. Gansbacher, and E. Gilboa. 1994. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res. 54:1760.
32. Bubenick, J., J. Simova, J. Zeuthen, M. Diamant, T. Jandlova, and D. Bubenikova. 1994. Gene therapy of plasmacytoma: comparison of the therapeutic efficacy of tumor cells transduced with interleukin-2, interleukin-4, or interleukin-6 genes. Folia Biol. (Prague) 40:29.
33. Germann, T., M. Bongartz, H. Dlugonska, H. Hess, E. Schmitt, L. Kolbe, E. Kolsch, F. J. Podlaski, M. K. Gately, and E. Rude. 1998. Interleukin 12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. Eur. J. Immunol. 25:823.
34. Hara, I., Y. Takechi, and A. Houghton. 1995. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the Brown locus protein. J. Exp. Med. 182:1606.
35. Morton, D., L. J. Foshag, D. S. B. Hoon, J. A. Nizze, L. A. Wanek, C. Chang, D. G. Davtyan, R. K. Gupta, R. Elastoff, and R. F. Irie. 1992. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. 216:463.
36. North, R. J. 1985. Down regulation of the antitumor immune response. Adv. Cancer Res. 45:1.
37. + T cells in mice bearing an advanced sarcoma augments the antitumor action of interleukin-2. Cancer Immunol. Immunother. 38:107.
38. Koeppen, H. K. W., S. Singh, H. J. Stauss, B. H. Park, D. W. Rowley, and H. Schreiber. 1993. CD4-positive and B-lymphocytes in transplantation immunity. Transplantation 55:1349.
39. Tahara, H., L. Zitvogel, W. J. Storkus, H. J. Zeh III, T. G. McKinney, R. D. Schreiber, U. Gubler, P. D. Robbins, and M. T. Lotze. 1995. Effective eradication of established murine tumors with IL-12 therapy using a polycistronic retroviral vector. J. Immunol. 154:6466.
40. Kundig, T. M., M. F. Bachmann, C. Di Paolo, J. J. L. Simard, M. Battegay, H. Lother, A. Gessner, K. Kuhlcke, P. S. Ohashi, H. Hengartner, and R. M. Zinkernagel. 1995. Fibroblast as efficient antigen-presenting cells in lymphoid organs. Science 268:1343.
41. Brichard, V., G. Warnier, A. Van Pel, G. Morlighen, S. Lucas, and T. Boon. 1995. Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815. Eur. J. Immunol. 25:664.